These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38036098)

  • 81. CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target.
    Terasaki M; Sugita Y; Arakawa F; Okada Y; Ohshima K; Shigemori M
    Brain Tumor Pathol; 2011 Apr; 28(2):89-97. PubMed ID: 21210239
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells.
    Yoshida D; Koketshu K; Nomura R; Teramoto A
    J Neurooncol; 2010 Oct; 100(1):51-64. PubMed ID: 20309720
    [TBL] [Abstract][Full Text] [Related]  

  • 83. CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR.
    Circelli L; Sciammarella C; Guadagno E; Tafuto S; del Basso de Caro M; Botti G; Pezzullo L; Aria M; Ramundo V; Tatangelo F; Losito NS; Ieranò C; D'Alterio C; Izzo F; Ciliberto G; Colao A; Faggiano A; Scala S
    Oncotarget; 2016 Apr; 7(14):18865-75. PubMed ID: 26934559
    [TBL] [Abstract][Full Text] [Related]  

  • 84. CXCL12/CXCR4 promotes motility and proliferation of glioma cells.
    do Carmo A; Patricio I; Cruz MT; Carvalheiro H; Oliveira CR; Lopes MC
    Cancer Biol Ther; 2010 Jan; 9(1):56-65. PubMed ID: 19923906
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression.
    Koshiba T; Hosotani R; Miyamoto Y; Ida J; Tsuji S; Nakajima S; Kawaguchi M; Kobayashi H; Doi R; Hori T; Fujii N; Imamura M
    Clin Cancer Res; 2000 Sep; 6(9):3530-5. PubMed ID: 10999740
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
    Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
    J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis.
    Hall JM; Korach KS
    Mol Carcinog; 2013 Sep; 52(9):715-25. PubMed ID: 22549810
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis.
    Zhuo W; Jia L; Song N; Lu XA; Ding Y; Wang X; Song X; Fu Y; Luo Y
    Clin Cancer Res; 2012 Oct; 18(19):5387-98. PubMed ID: 22932666
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice.
    Saha A; Ahn S; Blando J; Su F; Kolonin MG; DiGiovanni J
    Cancer Res; 2017 Sep; 77(18):5158-5168. PubMed ID: 28687617
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Relationship between chemokine axis CXCL12-CXCR4 and epithelial ovarian cancer].
    Guo Q; Wu XH; Lü YP; Yang B; Xu F; Zhang SJ
    Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(21):1677-80. PubMed ID: 24125682
    [TBL] [Abstract][Full Text] [Related]  

  • 91. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
    Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD
    Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
    Khan MA; Srivastava SK; Zubair H; Patel GK; Arora S; Khushman M; Carter JE; Gorman GS; Singh S; Singh AP
    J Biol Chem; 2020 Jun; 295(25):8413-8424. PubMed ID: 32358063
    [TBL] [Abstract][Full Text] [Related]  

  • 93. SDF-1α upregulation of MMP-2 is mediated by p38 MAPK signaling in pancreatic cancer cell lines.
    Pan F; Ma S; Cao W; Liu H; Chen F; Chen X; Shi R
    Mol Biol Rep; 2013 Jul; 40(7):4139-46. PubMed ID: 23712777
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases.
    Portella L; Vitale R; De Luca S; D'Alterio C; Ieranò C; Napolitano M; Riccio A; Polimeno MN; Monfregola L; Barbieri A; Luciano A; Ciarmiello A; Arra C; Castello G; Amodeo P; Scala S
    PLoS One; 2013; 8(9):e74548. PubMed ID: 24058588
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
    Yang F; Takagaki Y; Yoshitomi Y; Ikeda T; Li J; Kitada M; Kumagai A; Kawakita E; Shi S; Kanasaki K; Koya D
    Cancer Res; 2019 Feb; 79(4):735-746. PubMed ID: 30584072
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Artemin regulates CXCR4 expression to induce migration and invasion in pancreatic cancer cells through activation of NF-κB signaling.
    Wang J; Wang H; Cai J; Du S; Xin B; Wei W; Zhang T; Shen X
    Exp Cell Res; 2018 Apr; 365(1):12-23. PubMed ID: 29453972
    [TBL] [Abstract][Full Text] [Related]  

  • 97. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
    Benedicto A; Romayor I; Arteta B
    Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.
    Heidegger I; Fotakis G; Offermann A; Goveia J; Daum S; Salcher S; Noureen A; Timmer-Bosscha H; Schäfer G; Walenkamp A; Perner S; Beatovic A; Moisse M; Plattner C; Krogsdam A; Haybaeck J; Sopper S; Thaler S; Keller MA; Klocker H; Trajanoski Z; Wolf D; Pircher A
    Mol Cancer; 2022 Jun; 21(1):132. PubMed ID: 35717322
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells.
    Boudot A; Kerdivel G; Habauzit D; Eeckhoute J; Le Dily F; Flouriot G; Samson M; Pakdel F
    PLoS One; 2011; 6(6):e20898. PubMed ID: 21695171
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Application of chemokine receptor antagonist with stents reduces local inflammation and suppresses cancer growth.
    Mao AW; Jiang TH; Sun XJ; Peng J
    Tumour Biol; 2015 Nov; 36(11):8637-43. PubMed ID: 26044561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.